Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
RNS - Ikonisys SA: Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy

Company: Ikonisys S.A. Date: 2025-04-03 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
![](_page_0_Picture_0.jpeg)

# **Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy**

**Florence (Italy) and Paris (France), April 3, 2025** – **8:00 am CEST** – **ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO)**, announces that its Italian subsidiary **Hospitex International** has launched **Urine24.com**, the first online-available urinary cytology test for early bladder cancer diagnosis. The service is now available through its official website offering a non-invasive, fast, and highly reliable solution for millions of Italians.

# **Urine24 to Address a Critical Need in the Italian Market**

In Italy, bladder cancer is one of the most common malignancies, with approximately **29,200 new cases diagnosed annually** and a patient population of over **313,000**. The need for precise and efficient screening tools is therefore a top priority. With a retail price of **€68 per test**, the potential market for Urine24 in Italy exceeds **€23 million annually**, considering both new cases and the monitoring of recurrences, which occur in 60-70% of patients.

The test is recommended for individuals at higher risk of developing bladder cancer, including:

- **Smokers**, the leading risk factor for this malignancy (**approximately 8.6 million Italians**);
- **Workers exposed to chemicals**, such as dyes, paints, industrial solvents, and pesticides;
- **People with chronic urinary infections** or a history of recurrent cystitis;
- **Individuals with a family history of urothelial tumors**;
- **Those who have undergone radiation or chemotherapy treatments in the pelvic area**;
- **All individuals over the age of 50**, a group with a significantly increased risk of developing bladder cancer (**approximately 21.3 million Italians**).

Considering smokers and individuals over 50, the potential target population for Urine24 in Italy is approximately **29.9 million people**. If even **1% of this population** were to take the test annually, the potential market would be around **€20.4 million per year**, highlighting the urgent need for accessible, early and effective diagnostic solutions for prevention of bladder cancer.

# **Urine24: A Game-Changer in Bladder Cancer Screening**

Urine24 stands out for its use of advanced cytological technologies that allow the detection of cancerous cells in urine with **high sensitivity and specificity**. Urinary cytology is a well-established diagnostic test, but with Urine24, it is performed using a **thin-layer method**, which enhances sample quality, reduces false negatives, and increases result accuracy. Additionally, test interpretation follows **The Paris System**, an internationally standardized classification system that optimizes the identification of cellular abnormalities, providing clearer and more reliable results.

Beyond its advanced diagnostics, Urine24 offers seamless at-home experience, with home sample collection and delivery logistics, eliminating the need for hospital visits, and full digital report delivery.

## **A Rapidly Expanding Market Opportunity**

The initial conversion rates of the Urine24 test are extremely positive, indicating strong market demand. Based on this early data, Hospitex anticipates **steady revenue growth, reaching €3 million in revenue within the next two years for the Italian market**.

However, the potential of Urine24 extends beyond Italy. Bladder cancer is a major global health concern, with over **570,000 new cases diagnosed annually worldwide**, according to the World Health Organization. Europe and North America represent key expansion markets, with millions of high-risk individuals(aging populations, high prevalence of smoking, …) who would benefit from early screening.

Considering the broader international market, Urine24 has the potential to scale rapidly. Countries with aging populations, high smoking rates, and occupational exposure to carcinogenic chemicals represent key markets for expansion.

With the oncological diagnostics sector experiencing rapid expansion, with **annual growth forecasts exceeding 10% globally**, Urine24 is positioned as a highly scalable solution.

For more information, visit **www.urine24.com** website or contact Hospitex International's press office.

-----------------------

### **About ALIKO SCIENTIFIC (Ikonisys SA)**

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: [www.alikoscientific.com](http://www.alikoscientific.com/)

### **About IKONISYS**

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: [www.ikonisys.com](https://ikonisys.com/)

#### **About HOSPITEX**

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: [www.hospitex.com](https://hospitex.com/)

### **Contacts**

| Ikonisys               | NewCap                                     | NewCap                     |
|------------------------|--------------------------------------------|----------------------------|
| Alessandro Mauri       | Louis-Victor Delouvrier/Aurélie Manavarere | Nicolas Merigeau           |
| CFO                    | Investor Relations                         | Media Relations            |
| investors@ikonisys.com | ikonisys@newcap.eu                         | ikonisys@newcap.eu         |
|                        | Tel.: +33 (0)1 44 71 94 94                 | Tel.: +33 (0)1 44 71 94 98 |

#### **Disclaimer**

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forwardlooking information constitutes a guarantee of actual results.